广州地区HBV/HCV重叠感染患者流行及临床特征研究

目的 探讨广州地区乙型肝炎病毒/丙型肝炎病毒（HBV/HCV）重叠感染患者的流行及临床特征,为提高其诊治提供依据.方法 回顾2005年4月至2011年10月我院收治慢性HBV感染患者临床资料,分析HBV/HCV重叠感染患者流行特征,按照HBeAg状态以及HBV DNA、HCV RNA水平分组分析HBV/HCV重叠感染患者临床特征.结果 HBV/HCV重叠感染率为1.9％（128/6604）,主要见于伴静脉吸毒史的男性中年患者.HBeAg阳性与阴性重叠感染患者之间的生化指标和终末期肝病发生率均无差异.HBeAg阳性患者HBV DNA阳性率高于阴性患者（P ＜0.001）,而HCV RNA水平阳性率低于阴性患者（P =0.007）.HBV DNA阳性患者终末期肝病发生率较阴性组升高（58.1％比37.9％,P=0.027）,而HCV RNA阳性与阴性患者之间发生率相似（43.6％比49.2％,P=0.540）.结论 广州地区HBV/HCV重叠感染率较低,HBV DNA水平可能与患者的疾病进展相关.

Analysis on epidemiological and clinical features of patients with HBV/HCV co-infection in Guangzhou area

Objective To explore the epidemiological and clinical feature of hepatitis B virus and hepatitis C virus （HBV/HCV） co-infection in Guangzhou area,and provide evidence to elevate the diagnoses and treatment for the co-infection.Methods Data of patients with chronic HBV infection seen from April 2005 to October 2011 were retrospectively collected,and the epidemiological features of HBV/ HCV co-infection were analyzed.Patients with HBV/HCV co-infection were stratified according to the HBeAg status and the levels of HBV DNA and HCV RNA,and their clinical feature were analyzed.Results The prevalence of HBV/HCV co-infection was 1.9% （128/6604）,which was mainly seen in middle age of male populations with history of drug addiction.There were no significant differences in biochemical markers and percentage of end-stage liver disease between HBeAg positive and HBeAg negative co-infection patients.The HBV DNA positive rate in HBeAg positive patients was higher than those in HBeAg negative patients （P 〈 0.001）,while the HCV RNA positive rate was lower than those in HBeAg negative patients （P =0.007）.The frequency of end-stage liver disease in HBV DNA positive patients was higher than that in HBV DNA negative patients （58.1% vs.37.9%,P =0.027）,but it was similar between HCV RNA positive and negative patients （43.6% vs.49.2%,P =0.540）.Conclusions The prevalence of HBV/ HCV co-infection in Guangzhou area in low,and the levels of HBV DNA may associate with progression of disease.